article thumbnail

Zydus gets FDA approval for antibiotic drug azithromycin

Pharmaceutical Technology

Zydus, which currently has 360 approvals, has filed abbreviated new drug applications for more than 440 drugs since 2003-04. The vaccine, which generates the SARS-CoV-2 viral spike protein on administration, induces the immune system’s cellular and humoral arm-mediated immune response.

FDA 52
article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

The vaccination of patients with AN1792 led to the activation of their immune systems, which started producing endogenous anti-Abeta antibodies. Therefore, active immunotherapy to trigger the immune system to produce sustained levels of endogenous antibodies has now become far more attractive.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA approves Xolair to treat accidental exposure to food allergens

The Checkup by Singlecare

Xolair is not a new drug; it was originally approved in 2003 for the treatment of moderate to severe persistent allergic asthma in some patients. The most recent extension approved the medication to treat IgE-mediated food allergy, meaning food allergy involving an immune system reaction that begins quickly after ingesting the allergen.

FDA 103
article thumbnail

Reconfiguring COVID and influenza vaccines for long-term effectiveness

pharmaphorum

When exposed to a virus, one’s immune system develops antibodies in response to foreign antigens, with or without a vaccine. However, a vaccine trains the immune system to recognise that familiar virus and kill it more rapidly. Osivax’s technology, oligoDOM, trains the T-cell immune response to recognise the nucleoprotein.

article thumbnail

FDA approves Wezlana for inflammatory conditions

The Checkup by Singlecare

According to the FDA announcement, the most serious side effect of Wezlana is infection because the prescription affects your immune response. Crohn’s disease What are the possible side effects of Wezlana?

FDA 110
article thumbnail

HIV vaccines suffer setbacks but new approaches could turn the tide

Pharmaceutical Technology

A partial change in perspectives The RV144 trial that took place between 2003 and 2006 in Thailand r eported modest efficacy results , which generated enthusiasm for vaccines that induce responses from non-neutralising antibodies, says Montefiori.

Vaccines 117
article thumbnail

Developing new treatment regimens for HIV

European Pharmaceutical Review

For example, broadly neutralising antibodies (bNAbs), capsid inhibitors and maturation inhibitors all might play a role in fighting HIV from the initial binding and fusion of HIV into immune cells, to where it integrates into the cell, out to its assembly and maturation. References 1. World Health Organization. The Global Health Observatory.